亿帆医药股份有限公司 | | 辽宁亿帆药业有限公司 | 全资子公司 | 其他应收款 | 9,935.54 | 2,068.09 | 84.17 1,488.28 10,599.52 往来款 | | | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 合肥亿帆医药有限公司 | 全资子公司 | 其他应收款 | | 11,680.01 | | 5,644.03 | 6,035.98 往来款 | 非经营性往来 | | | 合肥亿帆生物制药有限公司 | 全资子公司 | 其他应收款 | 61,791.65 | 36,457.12 | 527.23 38,108.45 60,667.55 往来款 | | | 非经营性往来 | | | 欧芬迈迪（北京）生物技术有限公司 | 全资子公司 | 其他应收款 | 200.00 | | | | 200.00 往来款 | 非经营性往来 | | | 亿帆医药研究院（北京）有限公司 | 全资子公司 | 其他应收款 | 5,773.45 | 550.97 | 38.03 | 2,246.14 ...

独立董事独立意见 亿帆医药股份有限公司 独立董事关于第八届董事会第八次会议相关事项发表 的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司证券 发行管理办法》、《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》（以下简称"《规范运作》"）、《公 司章程》以及公司《独立董事工作制度》的有关规定，作为亿帆医药股份有限公 司（以下简称"公司"）的独立董事，对公司第八届董事会第八次会议审议的相 关事项发表独立意见如下： 关于公司2023年上半年计提资产减值准备的独立意见 2023 年 8 月 28 日 独立董事独立意见 （本页无正文，为独立董事关于亿帆医药股份有限公司第八届董事会第八次 会议相关事项发表的独立意见签字页。） 独立董事签署： GENHONG CHENG 刘洪泉 雷新途 经审阅，我们认为：公司本次计提资产减值准备遵循并符合《企业会计准则》 和公司相关制度的规定，审议程序合法，依据充分。计提资产减值准备后，财务 报表能够更加公允地反映公司的财务状况和资产价值，符合公司实际情况，不存 在损害公司及全体股东特别是中小股东利益的情形 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2023-052 （二）会议以8票同意、0票反对、0票弃权的结果，审议通过了《关于2023 年半年度募集资金存放与使用情况的专项报告》 具体详见2023年8月30日登载于巨潮资讯网上的《关于2023年半年度募集资 金存放与使用情况的专项报告》。 （三）会议以8票同意、0票反对、0票弃权的结果，审议通过了《关于2023 年上半年计提资产减值准备的议案》 亿帆医药股份有限公司 第八届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 亿帆医药股份有限公司（以下简称"公司"）第八届董事会第八次会议于 2023 年 8 月 18 日以邮件的方式发出通知，于 2023 年 8 月 28 日以现场加通讯表 决的方式召开，其中以通讯表决方式参加会议的董事为程先锋先生、林行先生、 GENHONG CHENG 先生、雷新途先生、刘洪泉先生。会议应参加表决的董事 8 名，实际参加表决的董事 8 名，会议由董事长程先锋先生主持。本次会议的召集 和召开符合《公司法》和《公司章程》等有关 ...

证券代码：002019 证券简称：亿帆医药 亿帆医药股份有限公司投资者关系活动记录表 编号：2023002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | 其他（现场参与+网络视频直播） | | 参与单位名称及 | 现场投资者、线上投资者和参与文字问答的投资者 | | 人员姓名 | | | | 公司董事长兼总裁程先锋先生，副总裁李锡明先生，副总裁耿雨红 女士，董事兼副总裁林行先生，董事兼中药事业部发展业务负责人 | | 上市公司接待人 | 周本余先生，中药事业部创新业务负责人龚群先生，小分子事业部 | | 员姓名 | 负责人钱莉苹女士，国际事业部负责人李佳先生，财务总监喻海霞 | | | 女士，董事、副总裁兼董事会秘书冯德崎先生等 | | 时间 | 2023 年 6 月 2 日 13:00-15:00 | | 地点 | 合肥亿帆生物制药有限公司会议室、全景网"投资者关系互动平台" | | | （https://ir.p5w.net） | | 形式 | 现场+ ...

证券代码：002019 证券简称：亿帆医药 亿帆医药股份有限公司投资者关系活动记录表 | --- | |----------------| | | | 投资者关系活动 | | 类别 | | | | | | | | | | | | | | | | | | | | | | | | | | 活动参与人员 | | | | | | | | | | | | | | | | | | | | | | --- | |--------------------------------------------------------------| | 云；承珞资本：林田心；睿郡资产：魏志华；朴石投资：段越；尚 | | 石资本：贾鹏飞；鹤禧基金：吴迪龙；上海国鸣投资：张同鑫；问 | | 渠私募：胡德军；天弋投资：章轶；上海丰煜投资：文彧；上海聚 | | 宜投资：王坚；上海虹诗投资：王慧超；上海博亚：徐辉；联君资 | | 管：程建华；鹏扬基金：王雪刚；恒立基金：马犇；永唐盛世资管： | | 杜之鹏；上海名禹资管：王友红；鲸诚资产：万巍；泰霖投资：吕 | | 周延；盛熙基金：竺吉锋；易鑫安资管：于昕可；崇山投资：欧阳 | | 亦轩；昶元投 ...

Financial Performance - The net profit attributable to shareholders decreased by 21.93% after excluding non-recurring gains and losses[16] - Net profit attributable to shareholders of the listed company decreased by 46.59% to ¥64,774,428.20 from ¥121,266,909.58 year-on-year[38] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥59,978,038.28, down 21.93% from ¥76,821,416.28 in the previous year[38] - Basic and diluted earnings per share both decreased by 50.00% to ¥0.05 from ¥0.10 year-on-year[38] Revenue and Cash Flow - The total operating revenue for Q1 2023 was ¥938,532,039.13, representing a 3.60% increase compared to ¥905,920,591.79 in the same period last year[38] - The net cash flow from operating activities increased by 104.44% compared to the same period last year, mainly due to an increase in received payments[16] - The net cash flow generated from operating activities improved significantly to ¥2,042,875.34, compared to a negative cash flow of ¥46,018,343.12 in the same period last year, marking a 104.44% increase[38] - The company reported cash inflows from operating activities of CNY 1,077,790,038.41 in Q1 2023, an increase from CNY 1,007,886,294.93 in the same period last year, representing a growth of approximately 6.9%[58] - The company reported a decrease in cash outflows for operating activities, totaling CNY 1,075,747,163.07 in Q1 2023, compared to CNY 1,053,904,638.05 in Q1 2022, showing improved cash management[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,588,862,242.31, a slight increase of 0.36% from ¥12,543,503,416.06 at the end of the previous year[38] - The total current assets increased, with cash and cash equivalents reaching ¥1,214,966,438.53, up from ¥1,143,783,700.15[30] - The total liabilities increased to ¥3,423,082,919.34 from ¥3,397,259,755.63 year-on-year[38] - The company's financial assets decreased by 84.29% to 15,000,000.00 yuan, attributed to the redemption of financial products[40] Expenses and Impairments - Tax and additional charges increased by 54.14% to ¥10,831,847.60, primarily due to VAT and related taxes from inter-company transactions[8] - Other income decreased by 89.32% to ¥4,844,318.49, mainly due to a reduction in government subsidies received[8] - Operating costs rose to ¥480,751,477.19, compared to ¥427,472,846.50 in the same period last year[38] - The company recorded an asset impairment loss increase of 814.24% to ¥-1,221,138.65, mainly due to inventory impairment[19] - The company reported a significant reduction in credit impairment losses by 96.74% to ¥-124,882.34, attributed to the recovery of accounts receivable[8] Investments and Development - Investment income improved by 32.17%, with losses from joint ventures decreasing[8] - Research and development expenses for the period were ¥47,510,975.21, up from ¥38,302,629.24 in the previous year[33] - The company received several drug registration certificates, including for the injection of Sulfate Vincristine and other products, enhancing its product portfolio[25][28] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received a drug registration certificate for Lacosamide injection on March 10, 2023[48] - The company’s subsidiary, Yiyi Biopharmaceutical Development (Shanghai) Co., Ltd., received a clinical trial approval notice for the product F-652 on March 21, 2023[50] Financing Activities - Total cash inflow from financing activities was $1,112,952,122.70, compared to $814,866,505.67 in the prior period, reflecting a significant increase[78] - Cash outflow from financing activities amounted to $990,189,051.81, up from $460,883,663.95 in the previous year[78] - Net cash flow from financing activities was $122,763,070.89, a decrease from $353,982,841.72 year-over-year[78] - Cash received from borrowings was $1,112,216,128.41, an increase from $814,866,505.67 in the prior year[78] - Cash paid for debt repayment was $956,496,784.74, significantly higher than $436,316,371.62 in the previous period[78]

Financial Performance - The net profit attributable to shareholders decreased by 63.98% year-on-year, primarily due to an increase in government subsidies compared to the previous year[33]. - The net cash flow from operating activities increased by 56.71% year-on-year, mainly due to an increase in government subsidies received and tax refunds from national preferential policies[34]. - The company plans not to distribute cash dividends or bonus shares, nor to increase capital from reserves[16]. - The company reported a significant decline in pharmaceutical service revenue, leading to an increase in asset impairment provisions[33]. - The net profit attributable to shareholders in the fourth quarter significantly decreased compared to the previous three quarters due to the full impairment provision for R&D projects that could not meet expectations[37]. - The net profit excluding non-recurring gains and losses in the fourth quarter also saw a substantial decline, primarily due to government subsidies received during the quarter[37]. - Government subsidies recognized in the current period amounted to approximately ¥130.05 million, which is a key factor in the financial results[39]. - The total net profit after tax and minority interests for the fourth quarter was approximately ¥111.91 million, reflecting the impact of the aforementioned factors[39]. - The company’s operating revenue for 2022 was ¥3,836,640,799.74, a decrease of 12.98% compared to ¥4,409,035,585.85 in 2021[51]. - The net profit attributable to shareholders for 2022 was ¥191,277,350.92, down 31.29% from ¥278,398,951.02 in 2021[51]. - The net profit after deducting non-recurring gains and losses was ¥79,371,328.72, a decline of 63.98% compared to ¥220,375,153.57 in 2021[51]. - The net cash flow from operating activities increased by 56.71% to ¥472,065,141.66 in 2022, up from ¥301,231,402.96 in 2021[51]. - The total assets at the end of 2022 were ¥12,543,503,416.06, reflecting a 3.11% increase from ¥12,165,124,976.56 at the end of 2021[51]. - The net assets attributable to shareholders increased by 3.24% to ¥8,811,484,555.00 at the end of 2022, compared to ¥8,535,174,993.28 at the end of 2021[51]. - The company reported a basic earnings per share of ¥0.16 for 2022, down 30.43% from ¥0.23 in 2021[51]. - The weighted average return on equity for 2022 was 2.20%, a decrease of 1.08% from 3.28% in 2021[51]. Risk Management - The company has identified various risks in its operations, including R&D underperformance, goodwill impairment, exchange rate fluctuations, international business risks, and safety and environmental risks[5]. - The company has not experienced any substantial risks that could significantly impact its production and operations during the reporting period[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its future development statements[11]. Research and Development - The company is focusing on R&D projects, including the development of new products such as F-627 and F-652, which are currently under research[43]. - The company aims to leverage innovation to meet unmet clinical needs and enhance international competitiveness in the pharmaceutical sector[85]. - The company will adopt a cooperative and self-research approach for new product development, emphasizing innovation-driven strategies and green manufacturing initiatives[102]. - The company is committed to pursuing high-quality sustainable development by focusing on patient needs and avoiding homogenized competition in drug development[102]. - The company will focus on key traditional Chinese medicine products, enhancing development and academic construction to elevate product academic status and transition to mass branding[95]. - The company aims to strengthen its innovation capabilities in synthetic biology technology through collaboration with research institutions and self-built R&D teams, aligning with global trends[97]. - The company has improved its procurement system for core Chinese medicinal materials and key raw materials, ensuring optimal supplier performance in price, quality, and service[108]. - The company has established a complete independent system for R&D, procurement, production, and sales based on market demand and its actual situation[108]. - The company’s new product development is primarily based on independent R&D, supplemented by collaborations with overseas and domestic research institutions[112]. Market Position and Strategy - The company holds a leading position in the vitamin B5 market, with over 70% of its sales directed to Europe and the United States[69]. - The company plans to continue its market expansion and strategic acquisitions to enhance its competitive position in the pharmaceutical industry[43]. - The company is one of the few domestic firms to submit new drug applications for the same product simultaneously in the US, Europe, and China, indicating strong market positioning[88]. - The company has a high global market share in raw material drugs, with over 70% of Vitamin B5 products sold to Europe and the US, maintaining a leading position[88]. - The company’s sales strategy for the product Aibegesitin α injection mainly involves external authorization, receiving milestone payments and net sales royalties[110]. - The company’s core Chinese medicine products and key chemical drug products are produced based on market sales conditions and product demand plans[108]. Environmental Compliance - The company has established a comprehensive emergency response mechanism for environmental pollution incidents and has conducted multiple drills to enhance emergency handling capabilities[173]. - The company has achieved compliance in all monitored environmental discharge parameters, including wastewater and air emissions, with specific values such as 19.7 mg/L for biochemical oxygen demand and 8.5 mg/m³ for particulate matter[171]. - The company has implemented a "2022 Employee Stock Ownership Plan" to motivate and retain talent, alongside a comprehensive employee benefits system[177]. - The company has made significant investments in pollution control facilities, including a rotary kiln incinerator and a sludge dewatering machine, to ensure compliance with environmental regulations[171]. - The company has maintained transparency in information disclosure, enhancing communication with investors through various channels[176]. - The company has no recorded violations or penalties during the reporting period, indicating a strong compliance record[174]. - The company reported that it continues to meet environmental discharge standards for its operations[191]. - The company has established online monitoring systems for wastewater and air emissions, with data automatically uploaded to environmental authorities, ensuring compliance with national monitoring regulations[198]. - In 2022, all self-monitoring and supervisory monitoring results were compliant, demonstrating the company's effective pollution management capabilities[198]. - The company is actively conducting annual carbon emission audits to guide energy-saving measures across departments, aiming to reduce overall energy consumption[199]. Employee and Governance - The total number of employees is 4,338, with 1,092 in sales, 849 in technical roles, and 178 in finance[145]. - The company has implemented a training program for employees, focusing on various levels and roles to enhance skills and performance[146]. - The company’s governance structure includes various committees that have met multiple times to discuss performance evaluations and compensation plans[143]. - The company has a total of 36 employees with a PhD, 213 with a master's degree, and 1,278 with a bachelor's degree, indicating a strong educational background among staff[145]. - The employee stock ownership plan purchased a total of 7,292,100 shares, accounting for 0.59% of the company's total share capital, at an average price of RMB 10.765 per share, totaling approximately RMB 78.5 million[157]. - The company has implemented a dynamic management approach for its R&D projects, increasing investment in key products[138]. - The company plans to enhance its governance structure and internal control systems to improve operational compliance and investor relations[189].

现场参与地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥亿 帆生物制药有限公司一楼会议室。 亿帆医药股份有限公司（以下简称"公司"）于2023年4月15日在巨潮资讯 网上披露了《2022年年度报告》，为了让广大投资者更深入全面地了解公司经营 管理、发展战略、行业前景等情况，公司将举行2022年度业绩说明会，具体安排 如下： 一、说明会时间、地点和形式 股票代码：002019 股票简称：亿帆医药 公告编号：2023-030 亿帆医药股份有限公司 关于举行 2022 年度业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要事项提示： 会议时间：2023年6月2日（周五） 13:00-15:00 会议形式：现场参与+网络视频直播 欢迎广大投资者积极参与本次网上说明会。 （问题征集二维码） 召开时间：2023年6月2日（周五）13:00-15:00 召开形式：现场参与+网络视频直播 本次业绩说明会将采用"现场参与+网络视频直播"的方式实现线上线下同 步进行。线下会场设在安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥 亿帆生物制药有限公司一 ...

Group 1: Company Overview - The company is Zhejiang Hangzhou Xinfuyuan Pharmaceutical Co., Ltd. with stock code 002019 [1] - The investor relations activity took place on November 6, 2014, in Hefei, Anhui Province [2] Group 2: Investor Relations Activity - The event was categorized as an investor reception day, attended by various securities analysts and fund representatives [2] - Key company representatives included the Chairman, General Manager, Deputy General Manager, CFO, and Secretary of the Board [2] Group 3: Policy and Market Impact - Discussion on the potential impact of the National Development and Reform Commission's proposed drug price management reforms on the company [2][3] - The company does not base its development strategy solely on pricing but aims to strengthen its foundation through product diversification and vertical and horizontal industry development [3] Group 4: Future Development Directions - Future focus will be on the integration of pharmaceutical raw materials and products, with potential expansion into the healthcare industry [3] - Plans for overseas product development include product agency, ownership buyouts, and acquisitions of foreign companies [3] Group 5: Market Trends - Current pricing of calcium pantothenate is at a relatively low level, with future price trends difficult to predict; the company will adapt to market conditions [3]

Group 1: Company Overview - The company involved is Zhejiang Hangzhou Xinfuyuan Pharmaceutical Co., Ltd. [1] - The investor relations activity took place on July 31, 2014, at the company headquarters [1]. Group 2: Production and Operations - The supply and demand balance for calcium pantothenate products has been stable, but future price trends are difficult to predict [2]. - The PBS product line is not operating at full capacity due to slow market development, despite some market recovery [2]. - The company is managing production based on market sales to minimize losses from downtime [2]. Group 3: Major Asset Restructuring - The major asset restructuring was conditionally approved by the China Securities Regulatory Commission on July 3, 2014 [2]. - The company needs to submit additional materials regarding goodwill impairment risks and their impact on future performance [2][3]. - The company has complied with the requirements and submitted the necessary supplementary materials [3]. Group 4: Legal Matters - The company is involved in a trade secret infringement case with New Pharma, which was heard in the Shanghai High People's Court on July 3, 2014, with no verdict yet [3].